Abstract
ID Biomedical (formerly Intellivax International) is developing a trivalent nasal influenza vaccine, FluINsure, for the potential treatment of influenza. The vaccine is currently in phase II clinical trials.
MeSH terms
-
Administration, Intranasal
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Humans
-
Influenza Vaccines* / adverse effects
-
Influenza Vaccines* / chemistry
-
Influenza Vaccines* / therapeutic use
-
Influenza, Human / mortality
-
Influenza, Human / prevention & control*
-
Patents as Topic
-
Structure-Activity Relationship